Respiratory News and Research

RSS

Online self-management tool improves asthma patients' ability to reduce their symptoms

An online self-management tool for people with asthma has been shown to significantly improve their ability to reduce their symptoms. Researchers writing in BioMed Central's open access journal Respiratory Research tested the system in 200 adults with asthma, finding significant effects in those whose asthma was either partly controlled or uncontrolled at the beginning of the trial.

10 Jun 2010

$15 million sanctioned for replacement of school gas heaters not enough say organizations

The State Government of NSW has decided upon a $15 million replacement of nearly 100 school gas heaters especially targeting cold climate areas of NSW. The New South Wales Teachers Federation said in a statement that they will be urging the government to expand the programme to other areas replacing the unflued gas heaters in schools.

9 Jun 2010

Synteract joins Medidata's ASPire to Win channel partner program

Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that Synteract has joined Medidata's ASPire to Win® channel partner program. A full-service contract research organization (CRO) with an increasing global presence and extensive experience working with emerging biotech, pharmaceutical and medical device sponsors, Synteract will offer services around Medidata Rave®, the market-leading electronic data capture (EDC) and clinical data management (CDM) solution.

9 Jun 2010

Discovery Labs reports preliminary results from Surfaxin Phase 2 trial in children with Acute Respiratory Failure

Discovery Laboratories, Inc., reports preliminary results from its Phase 2 clinical trial of Surfaxin® in children with Acute Respiratory Failure (ARF), a critical condition often caused in children by severe respiratory infections. The objective of the study was to evaluate the safety and tolerability of intratracheal administration of Surfaxin and to assess whether Surfaxin treatment could decrease the duration of mechanical ventilation in children with ARF.

9 Jun 2010

Discovery Labs receives FDA guidance to gain Surfaxin approval for RDS in premature infants

Discovery Laboratories, Inc. announces today that it has received written guidance from the U.S. Food and Drug Administration (FDA) that is consistent with its ongoing, comprehensive preclinical program to resolve the sole remaining chemistry, manufacturing & control (CMC) issue necessary to potentially gain FDA marketing approval for Surfaxin® (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants.

9 Jun 2010

Aerovance reports top-line results from Aerovant Phase 2b clinical trial for eosinophilic asthma

Aerovance Inc. today announced top-line results from its Phase 2b clinical trial that show the inhaled dry powder formulation of Aerovant (pitrakinra inhalation powder) is effective in a pre-defined subset of patients with eosinophilic asthma.

8 Jun 2010

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

VIVUS, Inc. today announced that data from a previously reported phase 2 study evaluating the safety and efficacy of the investigational drug Qnexa for the treatment of obstructive sleep apnea were presented at SLEEP 2010, the 24th Annual Meeting of the Associated Professional Sleep Societies.

8 Jun 2010

Medicare bidding program will lead to 'suicide bidding', says Pennsylvania Association of Medical Suppliers

Providers of home medical equipment and services across Pennsylvania are proposing a fiscally responsible alternative to the mislabeled "competitive" bidding scheme currently under way in Medicare that will actually discourage competition, reduce access to care for many of Pennsylvania's more than two million Medicare beneficiaries, and put hundreds of Pennsylvania's homecare providers out of business.

8 Jun 2010

Rice University students develop new device to help children with acute respiratory infections

Gently, gently. That's how babies should be handled, and it was the prime consideration when a team of Rice University seniors developed a device that could save babies' lives.

8 Jun 2010

Masimo announces full market release of Rainbow Acoustic Monitoring to provide RRa

Masimo, the inventor of Pulse CO-Oximetry and Measure-Through Motion and Low Perfusion pulse oximetry, announced today the full market release of its latest medical technology breakthrough—Masimo Rainbow Acoustic Monitoring— providing continuous and noninvasive respiration rate that is accurate, easy-to-use, and enhances patient tolerance.

7 Jun 2010

BGS develops new bio filters for testing E. coli, salmonella, listeria and pseudomonas in food samples

BioSpec Global Solutions Inc., and partner -ICBS Ltd., announced today that it has begun development of three new bio filter for the testing of E. coli, salmonella, listeria and pseudomonas in food samples. Development of the Antibody/antigen multiple discrete filters and optical system for the simultaneous analysis of E.coli, salmonella, listeria and pseudomonas in food samples.

7 Jun 2010

Smoke-free laws protect both children and adults from exposure to secondhand smoke

Researchers at the Harvard School of Public Health (HSPH) have found that children and adolescents living in non-smoking homes in counties with laws promoting smoke-free public places have significantly lower levels of a common biomarker of secondhand smoke exposure than those living in counties with no smoke-free laws.

7 Jun 2010

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

Focusing on helping clinicians improve experiences for their patients, GE Healthcare is highlighting an innovative portfolio of molecular imaging technologies and agents at the 57th annual meeting of the Society of Nuclear Medicine, June 5-9, in Salt Lake City.

7 Jun 2010

Sleep apnea treatment remains effective between 31 and 53 months after beginning oral appliance therapy

According to new research that will be presented on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, between 31 and 53 months after beginning oral appliance therapy, the sleep apnea treatment remained effective. Subjective daytime sleepiness, fatigue severity, and quality of life also remained improved.

5 Jun 2010

High frequency ventilation for preterm babies just as effective

A University of Sydney study of ventilation strategies has shown that high-frequency oscillatory ventilation (HFOV) for preterm babies gives the same outcomes as conventional ventilation (CV).

4 Jun 2010

Unhealthy diet and lifestyle linked to childhood asthma - study

Asthma in children is on the rise worldwide and scientists have often blamed the environment for this trend. Britain has more than 1.1 million children and the US has nearly 10 million children with asthma. In a new international study diet has been cited to be a factor that affects asthma in children. The study on Allergies and Asthma in Childhood has shown what many parents knew for a while now – burgers are not good for children.

3 Jun 2010

FDA issues letter directing GSK to revise product labeling for Serevent and Advair

GlaxoSmithKline today announced that it has received a letter from the U.S. Food and Drug Administration directing revisions to product labeling for its respiratory products Serevent and Advair. The letter concludes discussions between GSK and the agency following FDA advisory committee meetings regarding the safety profile of long-acting beta2-agonists in the treatment of asthma, including salmeterol, the active ingredient in Serevent and one of the active ingredients in Advair.

3 Jun 2010

Motavizumab should not be licensed for marketing: FDA Antiviral Drugs Advisory Committee

MedImmune today announced that the U.S. Food and Drug Administration's Antiviral Drugs Advisory Committee has voted 14 to 3 to recommend that motavizumab should not be licensed for marketing regarding the prevention of serious respiratory syncytial virus disease in high-risk infants.

3 Jun 2010

CPAP treatment may be a better option for preterm infants

A national study involving a UT Southwestern Medical Center neonatologist provides new insight into how much oxygen preterm infants should receive as well as the optimal way to deliver it to them.

3 Jun 2010

McGill University granted 'Orphan Drug Designation' for pulmonary infection drug fenretinide

In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.

2 Jun 2010

Respiratory News and Research

Online self-management tool improves asthma patients' ability to reduce their symptoms

$15 million sanctioned for replacement of school gas heaters not enough say organizations

Synteract joins Medidata's ASPire to Win channel partner program

Discovery Labs reports preliminary results from Surfaxin Phase 2 trial in children with Acute Respiratory Failure

Discovery Labs receives FDA guidance to gain Surfaxin approval for RDS in premature infants

Aerovance reports top-line results from Aerovant Phase 2b clinical trial for eosinophilic asthma

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

Medicare bidding program will lead to 'suicide bidding', says Pennsylvania Association of Medical Suppliers

Rice University students develop new device to help children with acute respiratory infections

Masimo announces full market release of Rainbow Acoustic Monitoring to provide RRa

BGS develops new bio filters for testing E. coli, salmonella, listeria and pseudomonas in food samples

Smoke-free laws protect both children and adults from exposure to secondhand smoke

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

Sleep apnea treatment remains effective between 31 and 53 months after beginning oral appliance therapy

High frequency ventilation for preterm babies just as effective

Unhealthy diet and lifestyle linked to childhood asthma - study

FDA issues letter directing GSK to revise product labeling for Serevent and Advair

Motavizumab should not be licensed for marketing: FDA Antiviral Drugs Advisory Committee

CPAP treatment may be a better option for preterm infants

McGill University granted 'Orphan Drug Designation' for pulmonary infection drug fenretinide

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News